BIOL 351 | BIOL351 Module 9: Pharmacology
Updated and Latest Questions and Correct
Answers with Rationale - Portage Learning
1. A patient with a history of deep vein thrombosis is prescribed Warfarin. Which
pharmacogenomic test is most critical to perform before finalizing the initial dose to prevent
bleeding complications?
A. CYP2C9 and VKORC1 genetic variants
B. HLA-B*5701 allele screening
C. CYP2D6 polymorphism testing
D. TPMT enzyme activity assessment
Correct Answer: A
Explanation: Genetic testing for CYP2C9 and VKORC1 is essential for determining the
appropriate initial dose of Warfarin. These polymorphisms significantly influence the
metabolism and sensitivity of the drug in individual patients. Without this data, patients
are at a much higher risk for therapeutic failure or life-threatening hemorrhage. Utilizing
pharmacogenomics allows for a more precise dosing strategy that reaches a stable INR
faster. This approach exemplifies the shift toward personalized medicine to enhance
medication safety and efficacy.
2. A patient taking Clopidogrel for a recent coronary stent is also prescribed Omeprazole for
GERD. What is the primary concern regarding this drug-drug interaction?
A. Inhibition of Omeprazole absorption by Clopidogrel
B. Increased risk of gastric bleeding due to synergistic effects
C. Reduced antiplatelet efficacy due to CYP2C19 inhibition
D. Decreased renal excretion of Clopidogrel metabolites
Correct Answer: C
Explanation: Clopidogrel is a prodrug that requires conversion to its active form by the
CYP2C19 enzyme. Omeprazole is a potent inhibitor of this specific enzyme, preventing the
conversion from occurring effectively. This interaction leads to decreased antiplatelet
activity and increases the risk of stent thrombosis or myocardial infarction. Clinicians
should consider alternative acid-suppressing agents like Pantoprazole that have less
impact on CYP2C19. Maintaining therapeutic levels of antiplatelet agents is critical for post-
procedural cardiovascular safety.
,3. A patient presents with hyperthermia, muscle rigidity, and hyperreflexia after starting
Fluoxetine while still taking Phenelzine. Which condition is likely occurring?
A. Neuroleptic Malignant Syndrome
B. Anticholinergic Toxicity
C. Serotonin Syndrome
D. Malignant Hyperthermia
Correct Answer: C
Explanation: Serotonin syndrome occurs when two drugs that increase serotonin levels
are used concurrently, such as an SSRI and an MAOI. The combination results in
overstimulation of central and peripheral serotonin receptors, causing autonomic
instability. Common symptoms include tremor, hyperreflexia, agitation, and potentially
fatal hyperthermia. It is essential to allow a washout period of at least 14 days when
switching between these classes. Monitoring for these life-threatening symptoms is a vital
part of safe prescribing in psychiatric medicine.
4. According to the Beers Criteria, which of the following medications should generally be
avoided in geriatric patients due to the high risk of orthostatic hypotension and falls?
A. Lisinopril
B. Amitriptyline
C. Metformin
D. Atorvastatin
Correct Answer: B
Explanation: Amitriptyline is a tricyclic antidepressant with strong anticholinergic and
alpha-adrenergic blocking properties. In older adults, these properties significantly
increase the risk of orthostatic hypotension, sedation, and cognitive impairment. The Beers
Criteria highlights these risks as major contributors to falls and fractures in the elderly
population. Safer alternatives for depression or neuropathic pain should be prioritized in
this demographic. Medication safety in geriatrics requires careful consideration of the
physiological changes associated with aging.
5. A patient on Spironolactone for heart failure is started on Lisinopril for blood pressure
control. Which laboratory value requires the most frequent monitoring to ensure safety?
A. Serum sodium
B. Hemoglobin A1c
C. Serum calcium
D. Serum potassium
, Correct Answer: D
Explanation: Both Spironolactone and ACE inhibitors like Lisinopril have the potential to
increase serum potassium levels. When used together, they pose a significant risk for
hyperkalemia, which can lead to cardiac arrhythmias. Regular monitoring of renal function
and potassium is necessary to prevent adverse outcomes. Patients should be educated on
limiting high-potassium foods while on this regimen. This scenario demonstrates the
importance of managing drug-drug interactions through active laboratory surveillance.
6. Which pharmacogenomic marker must be tested before initiating Abacavir therapy to
avoid potentially fatal hypersensitivity reactions?
A. HLA-B*1502
B. HLA-B*5701
C. CYP2D6
D. G6PD deficiency
Correct Answer: B
Explanation: The HLA-B*5701 allele is highly associated with a hypersensitivity reaction
to the antiretroviral drug Abacavir. Testing for this genetic marker is mandatory in clinical
practice before the drug is prescribed. If a patient tests positive, they should never receive
Abacavir to prevent severe respiratory or gastrointestinal distress. This testing has
effectively reduced the incidence of Abacavir-induced hypersensitivity to nearly zero in
many populations. It serves as a gold standard example of utilizing pharmacogenomics for
patient safety.
7. An elderly patient with chronic kidney disease (CKD) is prescribed Digoxin. Why is this
patient at increased risk for toxicity compared to a younger patient with normal renal
function?
A. Increased volume of distribution for Digoxin
B. Enhanced hepatic metabolism of Digoxin in CKD
C. Decreased gastrointestinal absorption of Digoxin
D. Reduced renal clearance leading to drug accumulation
Correct Answer: D
Explanation: Digoxin is primarily eliminated from the body via renal excretion through the
kidneys. In patients with chronic kidney disease, the clearance of the drug is significantly
diminished, leading to elevated blood levels. Toxicity can manifest as visual disturbances,
bradycardia, and nausea, which can be life-threatening. Adjusting the dose based on the
calculated glomerular filtration rate (GFR) is essential for safety. Close monitoring of serum
digoxin levels is required for all patients with impaired renal function.
Updated and Latest Questions and Correct
Answers with Rationale - Portage Learning
1. A patient with a history of deep vein thrombosis is prescribed Warfarin. Which
pharmacogenomic test is most critical to perform before finalizing the initial dose to prevent
bleeding complications?
A. CYP2C9 and VKORC1 genetic variants
B. HLA-B*5701 allele screening
C. CYP2D6 polymorphism testing
D. TPMT enzyme activity assessment
Correct Answer: A
Explanation: Genetic testing for CYP2C9 and VKORC1 is essential for determining the
appropriate initial dose of Warfarin. These polymorphisms significantly influence the
metabolism and sensitivity of the drug in individual patients. Without this data, patients
are at a much higher risk for therapeutic failure or life-threatening hemorrhage. Utilizing
pharmacogenomics allows for a more precise dosing strategy that reaches a stable INR
faster. This approach exemplifies the shift toward personalized medicine to enhance
medication safety and efficacy.
2. A patient taking Clopidogrel for a recent coronary stent is also prescribed Omeprazole for
GERD. What is the primary concern regarding this drug-drug interaction?
A. Inhibition of Omeprazole absorption by Clopidogrel
B. Increased risk of gastric bleeding due to synergistic effects
C. Reduced antiplatelet efficacy due to CYP2C19 inhibition
D. Decreased renal excretion of Clopidogrel metabolites
Correct Answer: C
Explanation: Clopidogrel is a prodrug that requires conversion to its active form by the
CYP2C19 enzyme. Omeprazole is a potent inhibitor of this specific enzyme, preventing the
conversion from occurring effectively. This interaction leads to decreased antiplatelet
activity and increases the risk of stent thrombosis or myocardial infarction. Clinicians
should consider alternative acid-suppressing agents like Pantoprazole that have less
impact on CYP2C19. Maintaining therapeutic levels of antiplatelet agents is critical for post-
procedural cardiovascular safety.
,3. A patient presents with hyperthermia, muscle rigidity, and hyperreflexia after starting
Fluoxetine while still taking Phenelzine. Which condition is likely occurring?
A. Neuroleptic Malignant Syndrome
B. Anticholinergic Toxicity
C. Serotonin Syndrome
D. Malignant Hyperthermia
Correct Answer: C
Explanation: Serotonin syndrome occurs when two drugs that increase serotonin levels
are used concurrently, such as an SSRI and an MAOI. The combination results in
overstimulation of central and peripheral serotonin receptors, causing autonomic
instability. Common symptoms include tremor, hyperreflexia, agitation, and potentially
fatal hyperthermia. It is essential to allow a washout period of at least 14 days when
switching between these classes. Monitoring for these life-threatening symptoms is a vital
part of safe prescribing in psychiatric medicine.
4. According to the Beers Criteria, which of the following medications should generally be
avoided in geriatric patients due to the high risk of orthostatic hypotension and falls?
A. Lisinopril
B. Amitriptyline
C. Metformin
D. Atorvastatin
Correct Answer: B
Explanation: Amitriptyline is a tricyclic antidepressant with strong anticholinergic and
alpha-adrenergic blocking properties. In older adults, these properties significantly
increase the risk of orthostatic hypotension, sedation, and cognitive impairment. The Beers
Criteria highlights these risks as major contributors to falls and fractures in the elderly
population. Safer alternatives for depression or neuropathic pain should be prioritized in
this demographic. Medication safety in geriatrics requires careful consideration of the
physiological changes associated with aging.
5. A patient on Spironolactone for heart failure is started on Lisinopril for blood pressure
control. Which laboratory value requires the most frequent monitoring to ensure safety?
A. Serum sodium
B. Hemoglobin A1c
C. Serum calcium
D. Serum potassium
, Correct Answer: D
Explanation: Both Spironolactone and ACE inhibitors like Lisinopril have the potential to
increase serum potassium levels. When used together, they pose a significant risk for
hyperkalemia, which can lead to cardiac arrhythmias. Regular monitoring of renal function
and potassium is necessary to prevent adverse outcomes. Patients should be educated on
limiting high-potassium foods while on this regimen. This scenario demonstrates the
importance of managing drug-drug interactions through active laboratory surveillance.
6. Which pharmacogenomic marker must be tested before initiating Abacavir therapy to
avoid potentially fatal hypersensitivity reactions?
A. HLA-B*1502
B. HLA-B*5701
C. CYP2D6
D. G6PD deficiency
Correct Answer: B
Explanation: The HLA-B*5701 allele is highly associated with a hypersensitivity reaction
to the antiretroviral drug Abacavir. Testing for this genetic marker is mandatory in clinical
practice before the drug is prescribed. If a patient tests positive, they should never receive
Abacavir to prevent severe respiratory or gastrointestinal distress. This testing has
effectively reduced the incidence of Abacavir-induced hypersensitivity to nearly zero in
many populations. It serves as a gold standard example of utilizing pharmacogenomics for
patient safety.
7. An elderly patient with chronic kidney disease (CKD) is prescribed Digoxin. Why is this
patient at increased risk for toxicity compared to a younger patient with normal renal
function?
A. Increased volume of distribution for Digoxin
B. Enhanced hepatic metabolism of Digoxin in CKD
C. Decreased gastrointestinal absorption of Digoxin
D. Reduced renal clearance leading to drug accumulation
Correct Answer: D
Explanation: Digoxin is primarily eliminated from the body via renal excretion through the
kidneys. In patients with chronic kidney disease, the clearance of the drug is significantly
diminished, leading to elevated blood levels. Toxicity can manifest as visual disturbances,
bradycardia, and nausea, which can be life-threatening. Adjusting the dose based on the
calculated glomerular filtration rate (GFR) is essential for safety. Close monitoring of serum
digoxin levels is required for all patients with impaired renal function.
